Unique ID issued by UMIN | UMIN000043966 |
---|---|
Receipt number | R000050219 |
Scientific Title | Exploratory study on effects of plant extract-containing beverages against variations in a menopausal women's physical condition |
Date of disclosure of the study information | 2021/04/19 |
Last modified on | 2022/04/27 14:18:53 |
Exploratory study on effects of plant extract-containing beverages against variations in a menopausal women's physical condition
Exploratory study on effects of plant extract-containing beverages against variations in a menopausal women's physical condition
Exploratory study on effects of plant extract-containing beverages against variations in a menopausal women's physical condition
Exploratory study on effects of plant extract-containing beverages against variations in a menopausal women's physical condition
Japan |
none
Not applicable | Adult |
Others
NO
The aim of this study is to exploratorily examine a healthy menopausal female subjects' characteristic with ingestion of a plant extract-containing beverage to the subjects continuously for approximately 8 weeks, by confirming the ingestion-deriving some kind of change in physical condition and mood of the female subjects, ranging in age from 40 to 60, who realize that the subjects themselves are in a state of fatigue feeling.
Safety,Efficacy
Exploratory
Not applicable
1. Score on Chalder fatigue scale
2. Mood state on short version of POMS2
3. The autonomic nervous activity level (High Frequency, Low Frequency)
4. The autonomic nervous system balance (LF / HF ratio)
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
NO
2
Treatment
Food |
Oral ingestion of the test beverage (200 mL) to the subject, once a day for 8 weeks.
Oral ingestion of the placebo beverage (200 mL) to the subject, once a day for 8 weeks.
40 | years-old | <= |
60 | years-old | > |
Female
1) Subjects who can give informed consent to participate in this trial after being provided with an explanation of the experimental protocol detail.
2) Healthy female subjects ranging in age from 40 to 60 at informed consent.
3) At a point of the screening test, subjects who realize that the subjects themselves are in a steady state of fatigue feeling.
4) Subjects ranging in BMI from not less than 18.6 to less than 30.0 kg/m2.
5) Subjects who have an irregular menstrual period with not less than a week, or who have been amenorrhea for no more than 5 years.
1) Subjects with food allergy.
2) Subjects who have any difficulty in taking plant extract-containing foods (applicable to those who present symptoms of headache due to taste-related reasons and plant extract intakes).
3) Pregnant, possibly pregnant, or lactating subjects.
4) Subjects who have the habit of smoking, at the present time and/or within the past year before this trial.
5) Subjects with menopausal symptoms due to surgical treatments just like ovariectomy, and so on.
6) Subjects with serious or progressive chronic diseases/symptoms.
7) At a point of the screening test, subjects having infection history of COVID-19, and realizing that the subjects themselves are in the upward trend in fatigue feeling after the infection.
8) Subjects with a continuous remedy for chronic disease, accompanied by medication.
9) Subjects taking in the following foods that might affect menopausal symptoms; medicine (sleep inducers, antidepressants, antihypertensives, hormones, estrogen receptor-selective modulators for osteoporosis (SERMs), gynecological Chinese medicine), over-the-counter drugs (OTCs), health foods including health-specific/functional foods, with a frequency of no more than 5 days a week for over one month.
10) Subjects who took part in the other clinical/monitoring tests (limited to those involving oral intake or drug administration) within a month before giving informed consent to take part in this trial.
11) Others who have been determined as ineligible for participation in this trial, judging from the principal/sub investigator.
60
1st name | Shukuko |
Middle name | |
Last name | Ebihara |
Chiyoda Paramedical Care Clinic
Director
101-0047
2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
03-5297-5548
cpcc-contact@cpcc.co.jp
1st name | Makoto |
Middle name | |
Last name | Ichinohe |
CPCC Company Limited
Clinical Planning Department
101-0047
4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
03-5297-3112
cpcc-contact@cpcc.co.jp
CPCC Company Limited
Meiji Co., Ltd.
Profit organization
Institutional Review Board of Chiyoda Paramedical Care Clinic
2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
03-5297-5548
IRB@cpcc.co.jp
NO
2021 | Year | 04 | Month | 19 | Day |
Unpublished
Completed
2021 | Year | 03 | Month | 25 | Day |
2021 | Year | 03 | Month | 19 | Day |
2021 | Year | 05 | Month | 20 | Day |
2021 | Year | 08 | Month | 19 | Day |
2021 | Year | 11 | Month | 24 | Day |
2021 | Year | 12 | Month | 01 | Day |
2022 | Year | 04 | Month | 04 | Day |
2021 | Year | 04 | Month | 19 | Day |
2022 | Year | 04 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050219
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |